HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Novel benzimidazole inhibitors bind to a unique site in the kinesin spindle protein motor domain.

Abstract
Affinity selection-mass spectrometry (AS-MS) screening of kinesin spindle protein (KSP) followed by enzyme inhibition studies and temperature-dependent circular dichroism (TdCD) characterization was utilized to identify a series of benzimidazole compounds. This series also binds in the presence of Ispinesib, a known anticancer KSP inhibitor in phase I/II clinical trials for breast cancer. TdCD and AS-MS analyses support simultaneous binding implying existence of a novel non-Ispinesib binding pocket within KSP. Additional TdCD analyses demonstrate direct binding of these compounds to Ispinesib-resistant mutants (D130V, A133D, and A133D + D130V double mutant), further strengthening the hypothesis that the compounds bind to a distinct binding pocket. Also importantly, binding to this pocket causes uncompetitive inhibition of KSP ATPase activity. The uncompetitive inhibition with respect to ATP is also confirmed by the requirement of nucleotide for binding of the compounds. After preliminary affinity optimization, the benzimidazole series exhibited distinctive antimitotic activity as evidenced by blockade of bipolar spindle formation and appearance of monoasters. Cancer cell growth inhibition was also demonstrated either as a single agent or in combination with Ispinesib. The combination was additive as predicted by the binding studies using TdCD and AS-MS analyses. The available data support the existence of a KSP inhibitory site hitherto unknown in the literature. The data also suggest that targeting this novel site could be a productive strategy for eluding Ispinesib-resistant tumors. Finally, AS-MS and TdCD techniques are general in scope and may enable screening other targets in the presence of known drugs, clinical candidates, or tool compounds that bind to the protein of interest in an effort to identify potency-enhancing small molecules that increase efficacy and impede resistance in combination therapy.
AuthorsPayal R Sheth, Gerald W Shipps Jr, Wolfgang Seghezzi, Catherine K Smith, Cheng-Chi Chuang, David Sanden, Andrea D Basso, Lev Vilenchik, Kimberly Gray, D Allen Annis, Elliott Nickbarg, Yao Ma, Brian Lahue, Ronald Herbst, Hung V Le
JournalBiochemistry (Biochemistry) Vol. 49 Issue 38 Pg. 8350-8 (Sep 28 2010) ISSN: 1520-4995 [Electronic] United States
PMID20718440 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Benzamides
  • Benzimidazoles
  • KIF11 protein, human
  • Nucleotides
  • Quinazolines
  • ispinesib
  • benzimidazole
  • Adenosine Triphosphatases
  • Kinesins
Topics
  • Adenosine Triphosphatases (antagonists & inhibitors, metabolism)
  • Antineoplastic Agents (antagonists & inhibitors, pharmacology, therapeutic use)
  • Benzamides (metabolism)
  • Benzimidazoles (antagonists & inhibitors, pharmacology)
  • Binding Sites
  • Circular Dichroism
  • Humans
  • Kinesins (antagonists & inhibitors, chemistry, metabolism)
  • Mass Spectrometry
  • Nucleotides (antagonists & inhibitors, chemistry)
  • Protein Structure, Tertiary
  • Quinazolines (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: